Cargando…
Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation
Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use. As the main adverse event is bleeding, it is relevant whether edoxaban has additional effects on platelet function. We aimed to assess in vitro aggregation in patients with atrial...
Autores principales: | Sokol, Juraj, Nehaj, Frantisek, Ivankova, Jela, Mokan, Michal, Lisa, Lenka, Zolkova, Jana, Vadelova, Lubica, Mokan, Marian, Stasko, Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573709/ https://www.ncbi.nlm.nih.gov/pubmed/33054412 http://dx.doi.org/10.1177/1076029620948585 |
Ejemplares similares
-
First Evidence: TRAP-Induced Platelet Aggregation Is Reduced in Patients Receiving Xabans
por: Nehaj, Frantisek, et al.
Publicado: (2017) -
Impact of Dabigatran Treatment on Rotation Thromboelastometry
por: Sokol, Juraj, et al.
Publicado: (2021) -
COVID19 infection in a patient with paroxysmal nocturnal hemoglobinuria: A case report
por: Sokol, Juraj, et al.
Publicado: (2021) -
Outcomes of Patients with Newly Diagnosed Cardiac Myxoma: A Retrospective Multicentric Study
por: Nehaj, Frantisek, et al.
Publicado: (2018) -
How can Secondary Thromboprophylaxis in High-Risk Pregnant Patients
be Improved?
por: Stanciakova, Lucia, et al.
Publicado: (2022)